Shengxiang Ge
Xiamen University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shengxiang Ge.
PLOS ONE | 2010
Hai Yu; Quan Yuan; Shengxiang Ge; Hurng-Yi Wang; Yali Zhang; Qingrui Chen; Jun Yu Zhang; Pei-Jer Chen; Ningshao Xia
A novel hepatitis B virus (HBV) strain (W29) was isolated from serum samples in the northwest of China. Phylogenetic and distance analyses indicate that this strain is grouped with a series of distinct strains discovered in Vietnam and Laos that have been proposed to be a new genotype I. TreeOrderScan and GroupScan methods were used to study the intergenotype recombination of this special group. Recombination plots and tree maps of W29 and these putative genotype I strains exhibit distinct characteristics that are unexpected in typical genotype C strains of HBV. The amino acids of P gene, S gene, X gene, and C gene of all genotypes (including subtypes) were compared, and eight unique sites were found in genotype I. In vitro and in vivo experiments were also conducted to determine phenotypic characteristics between W29 and other representative strains of different genotypes obtained from China. Secretion of HBsAg in Huh7 cells is uniformly abundant among genotypes A, B, C, and I (W29), but not genotype D. HBeAg secretion is low in genotype I (W29), whose level is close to genotype A and much lower than genotypes B, C, and D. Results from the acute hydrodynamic injection mouse model also exhibit a similar pattern. From an overview of the results, the viral markers of W29 (I1) in Huh7 cells and mice had a more similar level to genotype A than genotype C, although the latter was closer to W29 in distance analysis. All evidence suggests that W29, together with other related strains found in Vietnam and Laos, should be classified into a new genotype.
The Journal of Infectious Diseases | 2006
Yj Zheng; Shengxiang Ge; Jun Zhang; Qs Guo; Mun Hon Ng; Fadi Wang; Ningshao Xia; Qingwu Jiang
BACKGROUND AND METHODS Genotype IV hepatitis E virus (HEV) has been isolated from humans and swine. To study the relationship between the human and swine reservoirs, we estimated their respective viral burden, analyzed the genetic makeup of the virus populations, and assessed the risk of infection associated with swine farming. RESULTS In 2 swine-farming districts of eastern China, 9.6% of swine and 0.3% of healthy human subjects excreted HEV in stool, as did 68.8% of patients with confirmed HEV infection. The virus population circulating in humans consisted of genotype I and at least 4 phylogenetically distinct subgroups of genotype IV viruses, 2 of which concurrently circulated among swine. Persons engaged in occupations related to swine farming were found to have a 74% higher risk of infection than those engaged in other occupations, and persons living in communities downstream of the swine farms were found to have a 29% higher risk of infection than persons living in communities upstream. CONCLUSIONS Genotype IV HEV is freely transmitted between humans and swine. Because the size of the swine population and its viral burden are much larger than those of humans, transmission of the virus most likely is directed from swine to humans. Infection can be acquired through contact with swine and their waste.
Emerging Infectious Diseases | 2006
Rongcheng Li; Shengxiang Ge; Yanping Li; Yj Zheng; Yi Nong; Qs Guo; Jun Zhang; Mun-Hon Ng; Ningshao Xia
HEV infection is thought to have been endemic in southern China for >60 years; swine are now the main source of human infection.
Vaccine | 2009
Jun Zhang; Chong-bo Liu; Rongcheng Li; Yimin Li; Yj Zheng; Yanping Li; Dong Luo; Bai-bin Pan; Yi Nong; Shengxiang Ge; Junhui Xiong; James Wai-Kuo Shih; Mun-Hon Ng; Ningshao Xia
The candidate recombinant hepatitis E vaccine, HEV 239, protect monkeys against infection by hepatitis E virus (HEV). The safety and immunogenicity of the vaccine for humans was assessed in a randomized controlled phase II clinical trial. The study was conducted in an endemic area of southern China and consisted of a dose scheduling, involving 457 adults and a dose escalation component involving 155 high school students. The results showed that the vaccine is safe and immunogenic for humans and suggest that it could prevent new HEV infection.
Journal of Hepatology | 2012
Chenghao Huang; Quan Yuan; Pei-Jer Chen; Yali Zhang; Chang-Rong Chen; Qingbing Zheng; Shiou-Hwei Yeh; Hai Yu; Yu Xue; Yixin Chen; Pingguo Liu; Shengxiang Ge; Jun Zhang; Ningshao Xia
BACKGROUND & AIMS This study aimed at investigating mutations in the hepatitis B surface protein (HBsAg) in occult hepatitis B virus (HBV) infection (OBI) and their influence on viral antigenicity and phenotype. METHODS The characteristics of 61 carriers with OBI (OBI group), 153 HBsAg(+) carriers with serum HBsAg ≤ 100 IU/ml (HBsAg-L group) and 54 carriers with serum HBsAg >100 IU/ml (HBsAg-H group) from 38,499 blood donors were investigated. Mutations in the major hydrophilic region (MHR) of the viral sequences were determined. Thirteen representative MHR mutations observed in OBI sequences were antigenically characterized with a panel of monoclonal antibodies (MAbs) and commercial HBsAg immunoassays and functionally characterized in HuH7 cells and hydrodynamically injected mice. RESULTS Of 61 OBI sequences, 34 (55.7%) harbored MHR mutations, which was significantly higher than the frequency in either the HBsAg-L (34.0%, p=0.003) or the HBsAg-H group (17.1%, p<0.001). Alterations in antigenicity induced by the 13 representative MHR mutations identified in the OBI group were assessed by reacting recombinant HBV mutants with 30 different MAbs targeting various epitopes. Four out of the 13 mutations (C124R, C124Y, K141E, and D144A) strongly decreased the analytical sensitivity of seven commercial HBsAg immunoassays, and 10 (G119R, C124Y, I126S, Q129R, S136P, C139R, T140I, K141E, D144A, and G145R) significantly impaired virion and/or S protein secretion in both HuH7 cells and mice. CONCLUSIONS MHR mutations alter antigenicity and impair virion secretion, both of which may contribute to HBsAg detection failure in individuals with OBI.
Angewandte Chemie | 2013
Dingbin Liu; Zhantong Wang; Albert J. Jin; Xinglu Huang; Xiaolian Sun; Fu Wang; Qiang Yan; Shengxiang Ge; Ningshao Xia; Gang Niu; Gang Liu; A. R. Hight Walker; Xiaoyuan Chen
Major State Basic Research Development Program of China (973 Program) [2013CB733802, 2014CB744503]; National Science Foundation of China (NSFC) [81101101, 51273165, 81201086, 81201190, 81371596]; Key Project of the Chinese Ministry of Education [212149]; Intramural Research Program (IRP) of the National Institute of Biomedical Imaging and Bioengineering (NIBIB); National Institutes of Health (NIH); NIH-NIBIB/NIST NRC
Journal of Clinical Microbiology | 2010
Qs Guo; Qiang Yan; Junhui Xiong; Shengxiang Ge; J. Wai-Kuo Shih; Mun-Hon Ng; Jun Zhang; Ningshao Xia
ABSTRACT A point prevalence study of hepatitis E virus (HEV) in Chinese blood donors was conducted, and the prevalences of antibodies against HEV immunoglobulin G (IgG) and IgM among Chinese blood donors were 32.60% and 0.94%, respectively. HEV viremia was 0.07%.
Transfusion | 2013
Chenyu Xu; Richard Wang; Cathy Schechterly; Shengxiang Ge; James Wai-Kuo Shih; Ningshao Xia; Naomi L.C. Luban; Harvey J. Alter
Hepatitis E virus (HEV) infection has become relevant to blood transfusion practice because isolated cases of blood transmission have been reported and because HEV has been found to cause chronic infection and severe liver disease in immunocompromised patients.
Journal of Clinical Microbiology | 2010
Quan Yuan; Shan-Hai Ou; Chang-Rong Chen; Shengxiang Ge; Bin Pei; Qingrui Chen; Qiang Yan; Yongcai Lin; Hongying Ni; Chenghao Huang; Anthony E. T. Yeo; James Wai-Kuo Shih; Jun Zhang; Ningshao Xia
ABSTRACT The characteristics of 30 carriers with occult hepatitis B virus (HBV) infection (OBI) were compared with those of 30 individuals diagnosed as being HBV carriers at the time of blood donation, 60 asymptomatic carriers, and 60 chronic hepatitis patients. The prevalence of genotype C was significantly higher in carriers with OBIs than in any other HBsAg-positive (HBsAg+) group (P < 0.001). Specific amino acid substitutions in the regions from amino acids 117 to 121 and amino acids 144 to 147 located in the major hydrophilic region of the S gene were associated with carriers with OBIs (P < 0.01 for carriers with OBIs versus HBsAg+ donors, carriers with OBIs versus HBsAg+ asymptomatic carriers, and carriers with OBIs versus HBsAg+ chronic hepatitis patients). G145R was the major variation in the HBV isolates responsible for local occult HBV infections.
Clinical and Vaccine Immunology | 2010
A. Li; Quan Yuan; Z. Huang; J. Fan; R. Guo; B. Lou; Qingbing Zheng; Shengxiang Ge; Yixin Chen; Zhijun Su; Anthony E. T. Yeo; Jun Zhang; Ning S. Xia
ABSTRACT A novel diagnostic immunoassay testing procedure for hepatitis B virus core antibody (anti-HBc) using homogeneous purified full-length hepatitis B virus core antigen (HBcAg) capsids obtained from Escherichia coli was compared with Abbott Architect anti-HBc chemiluminescent microparticle immunoassay (CMIA; indirect method) against a library of specimens. A monoclonal anti-HBc neutralization confirmatory assay was then used to determine the degree of discordance between specimens. The new assay was found to be superior in both sensitivity and specificity.